$AXGN
Axogen, Inc.

2024 Q2 Form 10-Q Financial Statement

#000080592824000072 Filed on May 02, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $47.91M $41.38M
YoY Change 25.57% 12.86%
Cost Of Revenue $12.57M $8.758M
YoY Change 73.87% 30.54%
Gross Profit $35.35M $32.62M
YoY Change 14.29% 8.9%
Gross Profit Margin 73.77% 78.83%
Selling, General & Admin $29.12M $29.77M
YoY Change -4.43% -2.76%
% of Gross Profit 82.37% 91.27%
Research & Development $6.658M $7.409M
YoY Change -9.57% 10.93%
% of Gross Profit 18.84% 22.71%
Depreciation & Amortization $1.657M $1.520M
YoY Change 107.64% 114.39%
% of Gross Profit 4.69% 4.66%
Operating Expenses $35.77M $37.18M
YoY Change -5.43% -0.31%
Operating Profit -$428.0K -$4.560M
YoY Change -93.8% -37.88%
Interest Expense -$1.494M $2.326M
YoY Change -1109.46% 14437.5%
% of Operating Profit
Other Income/Expense, Net -$1.493M -$2.075M
YoY Change -716.94% -877.15%
Pretax Income -$1.921M -$6.635M
YoY Change -71.16% -6.21%
Income Tax
% Of Pretax Income
Net Earnings -$1.921M -$6.635M
YoY Change -71.16% -6.21%
Net Earnings / Revenue -4.01% -16.04%
Basic Earnings Per Share -$0.04 -$0.15
Diluted Earnings Per Share -$0.04 -$0.15
COMMON SHARES
Basic Shares Outstanding 43.70M shares 43.21M shares
Diluted Shares Outstanding 43.71M shares 43.23M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.13M $17.63M
YoY Change -38.8% -53.43%
Cash & Equivalents $19.19M $15.71M
Short-Term Investments $1.944M $1.921M
Other Short-Term Assets $7.962M $9.181M
YoY Change -9.88% 5.47%
Inventory $28.02M $27.64M
Prepaid Expenses
Receivables $25.15M $24.21M
Other Receivables $0.00 $0.00
Total Short-Term Assets $82.26M $78.66M
YoY Change -4.54% -11.31%
LONG-TERM ASSETS
Property, Plant & Equipment $101.7M $103.1M
YoY Change 0.28% 6.36%
Goodwill
YoY Change
Intangibles $4.966M $4.768M
YoY Change 22.68% 23.59%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $106.7M $107.9M
YoY Change 1.14% 7.02%
TOTAL ASSETS
Total Short-Term Assets $82.26M $78.66M
Total Long-Term Assets $106.7M $107.9M
Total Assets $188.9M $186.5M
YoY Change -1.41% -1.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.66M $21.29M
YoY Change -5.37% 5.45%
Accrued Expenses $1.746M $1.639M
YoY Change 68.86% 57.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000K $5.000K
YoY Change -16.67% -28.57%
Total Short-Term Liabilities $23.42M $22.93M
YoY Change -2.16% 7.98%
LONG-TERM LIABILITIES
Long-Term Debt $47.05M $46.83M
YoY Change 1.93% 1.95%
Other Long-Term Liabilities $94.00K $23.59M
YoY Change -99.61% -4.81%
Total Long-Term Liabilities $47.14M $46.83M
YoY Change 2.14% 1.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.42M $22.93M
Total Long-Term Liabilities $47.14M $46.83M
Total Liabilities $93.25M $93.36M
YoY Change -1.32% 1.52%
SHAREHOLDERS EQUITY
Retained Earnings -$289.9M -$287.9M
YoY Change 6.05% 7.98%
Common Stock $385.5M $381.1M
YoY Change 4.07% 4.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.69M $93.16M
YoY Change
Total Liabilities & Shareholders Equity $188.9M $186.5M
YoY Change -1.41% -1.56%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.921M -$6.635M
YoY Change -71.16% -6.21%
Depreciation, Depletion And Amortization $1.657M $1.520M
YoY Change 107.64% 114.39%
Cash From Operating Activities $4.165M -$12.27M
YoY Change 1326.37% 65.24%
INVESTING ACTIVITIES
Capital Expenditures $1.232M $924.0K
YoY Change -73.66% -78.53%
Acquisitions
YoY Change
Other Investing Activities -$1.000K -$1.910M
YoY Change -100.01% -150.65%
Cash From Investing Activities -$1.233M -$3.251M
YoY Change -108.61% 313.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 544.0K $204.0K
YoY Change -39.42% -67.77%
NET CHANGE
Cash From Operating Activities 4.165M -$12.27M
Cash From Investing Activities -1.233M -$3.251M
Cash From Financing Activities 544.0K $204.0K
Net Change In Cash 3.476M -$15.31M
YoY Change -77.59% 102.13%
FREE CASH FLOW
Cash From Operating Activities $4.165M -$12.27M
Capital Expenditures $1.232M $924.0K
Free Cash Flow $2.933M -$13.19M
YoY Change -166.87% 12.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
437000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
431000 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380650000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
376530000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-287931000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281296000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
93156000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
95665000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
186516000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196827000 usd
CY2024Q1 us-gaap Revenues
Revenues
41378000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
101162000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43687729 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43687729 shares
CY2023Q1 us-gaap Revenues
Revenues
36664000 usd
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilityCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilityCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilitiesNoncurrent
CY2024Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilitiesNoncurrent
CY2024Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilityCurrent
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilityCurrent
CY2023Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilitiesNoncurrent
CY2024Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240331#LeaseLiabilitiesNoncurrent
CY2024Q1 us-gaap Liabilities
Liabilities
93360000 usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8758000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8172000 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
32620000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
28492000 usd
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19815000 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19446000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7409000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6326000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9956000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10061000 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
37180000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
35833000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4560000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7341000 usd
CY2024Q1 us-gaap Investment Income Net
InvestmentIncomeNet
293000 usd
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
549000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
2326000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
16000 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
65000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-185000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-81000 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2075000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
267000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7074000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43233149 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43233149 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42571021 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42571021 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7074000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1520000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
709000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
315000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
464000 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
71000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
222000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
219000 usd
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
255000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-267000 usd
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
367000 usd
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
581000 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
65000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-185000 usd
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
10000 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
426000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3919000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2954000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-681000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-175000 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4983000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1525000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
262000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
509000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7291000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2442000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-360000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-537000 usd
CY2024Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1000 usd
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12266000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7423000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
924000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4304000 usd
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1910000 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10203000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
CY2023Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
13974000 usd
CY2024Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
417000 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
253000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3251000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-786000 usd
CY2024Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1000 usd
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
207000 usd
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
634000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
204000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
633000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15313000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7576000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37026000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21535000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21713000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13959000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1656000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
516000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1026000 usd
CY2024Q1 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
290000 usd
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
326000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
95665000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3919000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2024Q1 axgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
207000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
93156000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31024000 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
6000000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
6002000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
100999000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7074000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2954000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2023Q1 axgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
634000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
97513000 usd
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Nature of Business</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen, Inc. (together with its wholly-owned subsidiaries, the “Company”) was incorporated in Minnesota. Our business is focused on the science, development and commercialization of the technologies used for peripheral nerve regeneration and repair. The Company's products include Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Texas and Ohio.</span></div>The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Reclassifications</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the condensed consolidated statement of operations for the three months ended March 31, 2024.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective as of the first quarter of 2024, the Company voluntarily changed its accounting policy for shipping and handling costs. Under the new accounting policy, these costs are included in Costs of goods sold, whereas they were previously included in Sales and marketing expenses. Including these expenses in Costs of goods sold better aligns these costs with the related revenue in the gross profit calculation. Although the prior method of accounting continues to be an accepted alternative, the new accounting policy is more widely used in the industry and provides improved comparability of the Company's financial statements to its peers. This change in accounting policy has been applied retrospectively. The consolidated statement of operations for the three months ended March 31, 2023, has been reclassified to reflect this change in accounting policy. The impact of this reclassification was an increase of $1,465 to cost of goods sold for the three months ended March 31, 2023, and a corresponding decrease to Sales and marketing expenses in the same period. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective as of the first quarter of 2024, the Company also ceased allocating certain costs to and from certain departments. Previously such costs had been allocated based on the Company’s estimate of the proportionate share of total expense to Cost of goods sold, Sales and marketing, Research and development, and General and administrative. The Company determined that these changes would better reflect industry practice and would provide more meaningful information as well as increased transparency of its operations. To conform the 2023 presentation to the current quarter’s presentation, $1,062 was reclassified to General and administrative, of which $353 was previously included in Research and development, $707 was previously included in Sales and marketing, and $2 was previously included in Cost of goods sold for the three months ended March 31, 2023, in the condensed consolidated statement of operations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These reclassifications had no impact on net revenue, loss from operations, net loss, or loss per common share for prior periods and do not represent a restatement of the Company's previously issued consolidated financial statements.</span></div>
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
14963000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15713000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21713000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37026000 usd
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
19901000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13545000 usd
CY2024Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1041000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2120000 usd
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6694000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7355000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
27636000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
23020000 usd
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
367000 usd
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
581000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
138000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
138000 usd
CY2024Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
103028000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
102427000 usd
CY2024Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
15190000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
13697000 usd
CY2024Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
87838000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
88730000 usd
CY2024Q1 us-gaap Depreciation
Depreciation
1520000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
709000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6305000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1969000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4335000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6006000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1907000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4099000 usd
CY2024Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
6737000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1969000 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4768000 usd
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
6438000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1907000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4531000 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
71000 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
1206000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
1298000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15247000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15562000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1639000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1541000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20663000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21123000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
28000 usd
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000 usd
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19000 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M6D
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1098
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1099
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1399
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1322
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid Remainder Of Fiscal Year
LesseeOperatingAndFinancingLeaseLiabilityToBePaidRemainderOfFiscalYear
2951000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid Year One
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne
4134000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid Year Two
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo
4269000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid Year Three
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree
3106000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid Year Four
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour
3104000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid After Year Four
LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFour
18565000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability To Be Paid
LesseeOperatingAndFinancingLeaseLiabilityToBePaid
36129000 usd
CY2024Q1 axgn Lessee Operating And Financing Lease Liability Undiscounted Excess Amount
LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount
13804000 usd
CY2024Q1 axgn Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
22325000 usd
CY2024Q1 axgn Operating And Financing Lease Liability Current
OperatingAndFinancingLeaseLiabilityCurrent
1644000 usd
CY2024Q1 axgn Operating And Financing Lease Liability Noncurrent
OperatingAndFinancingLeaseLiabilityNoncurrent
20681000 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3175000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3397000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
46825000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
46603000 usd
CY2024Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
CY2023Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
2147000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
222000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
219000 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
6000000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
6002000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3919000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2954000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7074000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43233149 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42571021 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43233149 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42571021 shares
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000805928-24-000072-index-headers.html Edgar Link pending
0000805928-24-000072-index.html Edgar Link pending
0000805928-24-000072.txt Edgar Link pending
0000805928-24-000072-xbrl.zip Edgar Link pending
axgn-20240331.htm Edgar Link pending
axgn-20240331.xsd Edgar Link pending
axgnfy24q1ex311.htm Edgar Link pending
axgnfy24q1ex312.htm Edgar Link pending
axgnfy24q1ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
preferabilityletterex18.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
axgn-20240331_def.xml Edgar Link unprocessable
axgn-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
axgn-20240331_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
axgn-20240331_cal.xml Edgar Link unprocessable
axgn-20240331_pre.xml Edgar Link unprocessable